Rankings
▼
Calendar
SNDX Q4 2021 Earnings — Syndax Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
SNDX
Syndax Pharmaceuticals, Inc.
$2B
Q4 2021 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$127M
+33209.5% YoY
Gross Profit
$126M
99.9% margin
Operating Income
$96M
75.6% margin
Net Income
$96M
76.0% margin
EPS (Diluted)
$1.81
QoQ Revenue Growth
+922.8%
Cash Flow
Operating Cash Flow
$101M
Free Cash Flow
$101M
Stock-Based Comp.
$4M
Balance Sheet
Total Assets
$450M
Total Liabilities
$41M
Stockholders' Equity
$408M
Cash & Equivalents
$222M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$127M
$380,000
+33209.5%
Gross Profit
$126M
$379,000
+33265.4%
Operating Income
$96M
-$20M
+582.1%
Net Income
$96M
-$20M
+571.0%
← FY 2021
All Quarters
Q1 2022 →